IGF-1 LR3, or Long R3 Insulin-like Growth Factor-1, is a synthetic analog of human Insulin-like Growth Factor-1. This modified peptide features an arginine substitution at position three and an N-terminal thirteen-amino acid extension. These alterations extend its half-life and reduce IGFBP binding, increasing bioavailability and IGF-1 receptor interaction.
Context
Within the somatotropic axis, endogenous IGF-1 is primarily synthesized in the liver in response to growth hormone. IGF-1 LR3 mimics native IGF-1 actions, yet its modified structure allows it to bypass some regulatory mechanisms. This offers a sustained, direct influence on cellular processes across various tissues, impacting growth and metabolic regulation.
Significance
Clinically, IGF-1 LR3 is significant for its potent anabolic properties, influencing tissue repair, muscle protein synthesis, and bone density. Its extended biological activity offers a sustained stimulus for cellular proliferation and differentiation. This analog is often explored in research for enhanced tissue regeneration or addressing muscle atrophy.
Mechanism
IGF-1 LR3’s action begins with high-affinity binding to the IGF-1 receptor (IGF-1R) on target cell surfaces. This interaction triggers intracellular signaling, notably the PI3K/Akt pathway, crucial for cell survival, growth, and protein synthesis. Reduced IGFBP affinity ensures more peptide remains free and biologically active, readily engaging its receptors.
Application
IGF-1 LR3 is primarily utilized in research to investigate its physiological effects and therapeutic potential, especially for muscle anabolism and tissue repair. While not broadly approved for human therapeutic use, investigational protocols may involve subcutaneous administration. Dosing varies and is not standardized for general clinical adoption, underscoring its experimental status.
Metric
Monitoring IGF-1 LR3 effects typically involves assessing changes in physiological markers, as direct serum measurement is not routinely available. Evaluation may include tracking lean body mass improvements, assessing body composition via DEXA, or observing metabolic parameter alterations. Clinical oversight focuses on the systemic impact on the individual’s physiological state and specific tissue responses.
Risk
The use of IGF-1 LR3 carries notable risks, especially without strict medical supervision. Potential adverse effects include hypoglycemia due to its insulin-mimetic properties. Concern exists regarding its mitogenic capacity to stimulate uncontrolled cell proliferation, potentially contributing to undiagnosed malignancies. Long-term human safety data are limited; improper use risks metabolic imbalances or unforeseen complications.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.